HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Svennevig, J. L. Articles by Froysaker, T. Search for Related Content PubMed PubMed Citation Articles by Svennevig, J. L. Articles by Froysaker, T.

The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 466-472, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits

JL Svennevig, OR Geiran, H Karlsen, T Pedersen, TE Mollnes, U Kongsgard and T Froysaker
Surgical Department A, Rikshospitalet, Oslo, Norway.

The degree of complement activation during cardiopulmonary bypass is considered a valuable parameter of biocompatibility of the extracorporeal circuit. In an in vitro setting with a heart-lung machine primed with fresh whole blood and saline solution, the C3 activation products C3b, iC3b, and C3c and the terminal complement complex were measured in double-antibody enzyme immunosorbent assays. No differences were found between seven sets treated with Duraflo II heparin coating and seven uncoated sets after 2 hours of circulation. C3 activation products (expressed as median and 95% confidence intervals) increased from 4.5 AU (2.8 to 12.3 AU) to 16.5 AU (10.0 to 19.4 AU) in the uncoated sets (p = 0.02) and from 4.6 AU (2.2 to 5.8 AU) to 19.3 AU (3.5 to 27.1 AU) in the coated sets (p = 0.02). Terminal complement complex increased from 5.7 AU (2.7 to 11.3 AU) to 13.6 AU (8.2 to 17.8 AU) in the uncoated sets (p = 0.02) and from 7.9 AU (4.6 to 11.4 AU) to 17.3 AU (9.4 to 35.1 AU) in the coated sets (p = 0.02). A significant drop in thrombocyte levels was observed in both coated and uncoated sets. In a supplementary series, the sterilization process did not influence the results. Although Duraflo II heparin coating is considered highly effective in preventing coagulation, it did not prevent complement activation in the present in vitro study. We hypothesize that the mode by which the heparin molecule is bound to the surface may be essential to obtain effects on both coagulation and complement system.

This article has been cited by other articles:

				The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]

				S. T Baksaas, H. I Flom-Halvorsen, E. Ovrum, V. Videm, T. E. Mollnes, F. Brosstad, and J. L Svennevig Leucocyte filtration during cardiopulmonary reperfusion in coronary artery bypass surgery Perfusion, March 1, 1999; 14(2): 107 - 117. [Abstract] [PDF]

				S T Baksaas, V Videm, T Pedersen, H Karlsen, T E Mollnes, F Brosstad, and J L Svennevig Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices Perfusion, March 1, 1999; 14(2): 119 - 127. [Abstract] [PDF]

				S. T Baksaas, V. Videm, E. Fosse, H. Karlsen, T. Pedersen, T. E Mollnes, T. A Hagve, and J. L Svennevig In vitro evaluation of new surface coatings for extracorporeal circulation Perfusion, January 1, 1999; 14(1): 11 - 19. [Abstract] [PDF]

				S T Baksaas, V Videm, T E Mollnes, S Tollofsrud, G Hetland, T Pedersen, and J L Svennevig Leucocyte filtration during cardiopulmonary bypass hardly changed leucocyte counts and did not influence myeloperoxidase, complement, cytokines or platelets Perfusion, December 1, 1998; 13(6): 429 - 436. [Abstract] [PDF]

				C B. Mahoney Heparin-bonded circuits: clinical outcomes and costs Perfusion, May 1, 1998; 13(3): 192 - 204. [Abstract] [PDF]

				D. Royston Surgery with cardiopulmonary bypass and pulmonary inflammatory responses Perfusion, May 1, 1996; 11(3): 213 - 219. [PDF]

				S. Daniel Review on the multifactorial aspects of bioincompatibility in CPB Perfusion, May 1, 1996; 11(3): 246 - 255. [Abstract] [PDF]

				A. Hamulu, B. Discigil, M. Ozbaran, T. Calkavur, E. Kara, A. Kokuludag, S. Buket, and O. Bilkay Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients Perfusion, January 1, 1996; 11(4): 333 - 337. [Abstract] [PDF]

				O. Moen, E. Fosse, V. Brockmeier, C. Andersson, T. E. Mollnes, K. Hogasen, and P. Venge Disparity in Blood Activation by Two Different Heparin-Coated Cardiopulmonary Bypass Systems Ann. Thorac. Surg., November 1, 1995; 60(5): 1317 - 1323. [Abstract] [Full Text]